Status:

TERMINATED

Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE)

Lead Sponsor:

NICHD Neonatal Research Network

Collaborating Sponsors:

National Center for Research Resources (NCRR)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Conditions:

Infant, Newborn

Hypoxia, Brain

Eligibility:

All Genders

Up to 6 years

Phase:

NA

Brief Summary

The Optimizing Cooling trial will compare four whole-body cooling treatments for infants born at 36 weeks gestational age or later with hypoxic-ischemic encephalopathy: (1) cooling for 72 hours to 33....

Detailed Description

Hypoxic-ischemic encephalopathy (HIE) is a rare, but life-threatening condition characterized by brain injury due to asphyxia diagnosed at or shortly after birth. According to the World Health Organiz...

Eligibility Criteria

Inclusion

  • Eligibility will be determined in a stepped process:
  • All infants with a gestational age ≥ 36 weeks will be screened for study entry if they are admitted to the NICU with a diagnosis of fetal acidosis, perinatal asphyxia, neonatal depression or encephalopathy.
  • Infants will be eligible if:
  • They have a pH ≤ 7.0 or a base deficit ≥ 16m mEq/ L on umbilical cord or any postnatal sample within 1 hour of age.
  • If, during this interval, they have a pH between 7.01 and 7.15, a base deficit is between 10 and 15.9 mEq/L, or a blood gas is not available, AND they have an acute perinatal event AND either a 10-minute Apgar score ≤ 5 or assisted ventilation initiated at birth and continued for at least 10 minutes.
  • Once these criteria are met, eligible infants will have a standardized neurological examination performed by a certified physician examiner. Infants will be candidates for the study when encephalopathy or seizures are present. For this study, encephalopathy is defined as the presence of 1 or more signs in 3 of the following 6 categories:
  • Level of consciousness: lethargy, stupor or coma;
  • Spontaneous activity: decreased, absent;
  • Posture: distal flexion, decerebrate;
  • tone: hypotonia, flaccid or hypertonia, rigid;
  • Primitive reflexes: a) suck, weak, absent; b) Moro, incomplete, flaccid;
  • Autonomic nervous system: a) pupils: constricted, unequal, skew deviation or non reactive to light; b) heart rate: bradycardia, variable heart rate or c) respiration: periodic breathing, apnea.
  • Eligible infants from multiple births will be enrolled in the same arm of the study.

Exclusion

  • Inability to randomize by 6 hours of age
  • Major congenital abnormality
  • Major chromosomal abnormality (including Trisomy 21),
  • Severe growth restriction (≤ 1800gm birth weight),
  • Infant is moribund and will not receive any further aggressive treatment,
  • Refusal of consent by parent
  • Refusal of consent by attending neonatologist
  • Infants with a core temperature \< 33.5°C for \> 1 hour at the time of screening by the research team would not be eligible for the study.

Key Trial Info

Start Date :

September 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2016

Estimated Enrollment :

364 Patients enrolled

Trial Details

Trial ID

NCT01192776

Start Date

September 1 2010

End Date

March 1 2016

Last Update

November 28 2025

Active Locations (19)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (19 locations)

1

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35233

2

University of California - Los Angeles

Los Angeles, California, United States, 90025

3

Stanford University

Palo Alto, California, United States, 94304

4

Emory University

Atlanta, Georgia, United States, 30303